Don’t Let Ebola Go Viral: What HCT/P Establishments Should Review Now
On July 10, 2026, the Food and Drug Administration (FDA) issued an important safety communication for human cell, tissue, and cellular and tissue-based product (HCT/P) establishments about Ebola disease caused by the Bundibugyo virus (species Orthoebolavirus bundibugyoense). The current Ebola outbreak in the Democratic Republic of the Congo and Uganda is being watched closely and the risk to the United States is currently considered low [1]. However, HCT/P establishments should consider whether their existing donor screening process is enough to address safety considerations for the products they recover, process, store, or distribute. This announcement is not a call for panic, but a call for disciplined review. The FDA did not issue a formal HCT/P donor eligibility guidance, but instead pointed establishments back to the core expectation under 21 CFR Part 1271 [2] to have written procedures, screen donors for relevant communicable disease risks, review clinical and physical evidence, document decisions, and revise procedures when risk changes. Let’s dive in!
The Announcement
FDA’s communication explains that the Centers for Disease Control and Prevention (CDC) [3] is monitoring an Ebola outbreak caused by the Bundibugyo virus disease, one of the orthoebolaviruses known to cause Ebola disease in humans. The outbreak began in the Democratic Republic of the Congo, with spread reported in Uganda. FDA noted that no U.S. cases had been confirmed as of the end of June 2026, and that federal agencies continue to monitor travelers. For HCT/P establishments, the real question is whether a donor may have been exposed before recovery and whether the establishment’s donor eligibility process would catch the risk before the tissue, cells, or related products move forward.
Why This Matters
HCT/P establishments operate in a regulated environment built around preventing the introduction, transmission, and spread of communicable disease. Under 21 CFR Part 1271, establishments must make donor eligibility determinations based on donor screening and testing. They must also establish, maintain, review, and revise written procedures for the steps they perform in donor screening, testing, and eligibility decisions. Ebola disease is severe, but HCT/P donor risk is not assessed the same way for every donor situation. A deceased tissue donor, a reproductive donor, or a living surgical bone or birth tissue donor may create different screening, timing, documentation, and product management questions. That is why a simple “add one question and move on” approach is usually not appropriate.
FDA’s communication highlights several voluntary screening considerations establishments may choose to build into their process. For example, reviewing relevant medical records and questions identifying if the donor, within the twenty-one (21) days before HCT/P recovery: 1) had an Ebola-related diagnosis, 2) suspected illness, 3) had close contact with an infected person, or 4) traveled to or resided in an area with widespread transmission or notification from a public health authority about possible exposure. These considerations should be compared against the donor’s medical history, donor risk assessment interview, physical assessment/examination process, chart review, recovery records, and any third-party screening tools. If the current process already captures fever, unexplained illness, travel, exposure to infectious disease, public health quarantine, or recent contact with a seriously ill person, confirm that your staff know how to apply those questions to Ebola disease risk. If the current process does not clearly capture these items, consider whether to add focused questions. Keep them straight-forward and operational so that staff should not have to interpret vague language during a time sensitive donor review.
The FDA states, “Based on information available at this time, establishments may also wish to consider whether, in the 21 days prior to HCT/P recovery, the donor:
Was diagnosed with or suspected of having Ebola disease
Had close contact with a person confirmed to have or suspected of having Ebola disease
Resided in or travelled to a country with widespread transmission of Ebola disease (See Map of Impacted Areas:https://www.cdc.gov/ebola/situation-summary/index.html)[4]
Was notified by a federal, state, or local public health authority that he or she may have been
exposed to a person with Ebola disease”
FDA’s Ebola disease notice for HCT/P establishments is best read as a prompt to review your organization’s donor screening process. Establishments should confirm that their donor eligibility process can identify Ebola-related illness, exposure, travel, residence, and public health notification risk during the relevant period before recovery. If gaps exist, update the process through normal quality change controls. If no gaps are found, document why the existing process is adequate. In other words, don’t wait for a crisis to find out whether your donor screening program can handle an emerging infectious disease signal. Review it now, document the rationale, train the team, and keep watching the public health updates.
Thanks for joining! Keep checking back as we continue to follow industry trends!
Have a question? Contact us here!
References:
[2] https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271